Israeli startup PhaseV has secured $50 million in Series A funding co-led by Accel and Insight Partners, with participation from existing investors Viola Ventures, LionBird and EXOR. This latest round brings the company's total funding to $65 million, following a $15 million raise in 2023.
PhaseV specializes in AI- and machine learning-enabled clinical development solutions for the life sciences industry. The company provides biopharma sponsors and clinical research organizations (CROs) with advanced insights across multiple domains, including clinical operations, causal disease modeling, treatment response pattern identification in complex heterogeneous data, and patient subgroup identification for precision medicine approaches.
"The pharma industry is at a critical crossroads, as traditional approaches to designing and executing clinical trials struggle to meet growing demands for speed, cost-efficiency and higher success rates," Raviv Pryluk, CEO and cofounder of PhaseV, said in a statement.
"This funding fuels our mission to support more pharma, biotech and CROs in embracing AI and machine learning to unlock the next era of clinical development. Our solutions deliver clear ROI by increasing trial success rates, reducing costs and accelerating time to market."
The company reports working with more than 30 global pharmaceutical companies that utilize its platform for clinical development initiatives. PhaseV has been actively building its network of industry partnerships over the past two years. Most recently, in early 2025, the company announced a collaboration with GI-focused clinical research organization Alimentiv.
This partnership follows several strategic alliances formed in 2024, including agreements with global biometric CRO Quanticate, clinical-stage drug development company NeuroSense Technologies, and oncology- and hematology-focused CRO iOMEDICO.
The new funding will allow PhaseV to expand its precision medicine capabilities and enhance its clinical development tools, addressing the pharmaceutical industry's growing need for more efficient, cost-effective, and successful clinical trials through advanced artificial intelligence and machine learning technologies.
Click here for the original news story.